InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,433.74
(
0.23%
)
US TECH 100
19,089.60
(
0.65%
)
Dow Jones
38,647.10
(
-0.17%
)
Brent Oil
82.16
(
0.22%
)
Bitcoin
66,743.85
(
-0.02%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 82
Posts 12466
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: biotech_researcher post# 54455

Thursday, 10/02/2014 12:41:29 PM

Thursday, October 02, 2014 12:41:29 PM

Post# of 80490
On second thought, what Dr, Ross Cambridge is doing at the University of Colorado with Ponatinib in FGFR1 lung cancer is really cutting edge. He is using Crowd Sourcing to gather enough patients across the United States to test Ponatinib on their mutations. Game changer stuff, and it says that may be lung cancer should be a part of Ariad's portfolio..
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up